颧上上颌神经阻滞与儿童腺扁桃体切除术中阿片类药物需求:一项随机临床试验
这项随机、盲法、前瞻性单中心研究纳入60例2-14岁拟行包膜内腺扁桃体切除术患儿,随机分为双侧颧上上颌神经阻滞组与对照组,分析53例。阻滞组恢复室阿片消耗量低于对照组,无阿片使用比例更高,FLACC评分更低,不良事件发生率两组相似。
要点
- 阻滞组恢复室阿片吗啡当量消耗0.07 mg/kg,低于对照组0.15 mg/kg。
- 阻滞组无阿片恢复室停留比例58%,高于对照组26%。
- 阻滞组FLACC评分0.7,低于对照组1.6;无阻滞相关并发症。
核心结论
- 颧上上颌神经阻滞是儿童包膜内腺扁桃体切除术后疼痛管理的有用辅助工具,可临床意义地减少术后阿片消耗且并发症风险低。
研究设计与样本
- 随机、盲法、前瞻性单中心三级儿童医院研究,纳入60例2-14岁拟行包膜内腺扁桃体切除术患儿,随机分为双侧颧上上颌神经阻滞组(阻滞组)与对照组,最终分析53例。
主要发现
- 恢复室停留期间阿片吗啡当量平均消耗量:阻滞组26例为0.07 mg/kg(SD 0.11),对照组27例为0.15 mg/kg(SD 0.14),平均差0.08(95%CI 0.01-0.15),Cohen d 0.64。
- 无阿片恢复室停留发生率:阻滞组7例(58%),对照组15例(26%),平均差32%(95%CI 5%-53%)。
- FLACC评分:阻滞组0.7,对照组1.6,平均差0.9(95%CI 0.2-1.6),Cohen d 0.7。
- 不良事件总体发生率两组相似,未报告神经阻滞相关并发症。
临床怎么用
- 原文结论认为颧上上颌神经阻滞是儿童包膜内腺扁桃体切除术后疼痛管理的有用辅助工具,可临床意义地减少术后阿片消耗且并发症风险低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pain management following pediatric adenotonsillectomies is opioid-inclusive, leading to potential complications. OBJECTIVE: To investigate the use of suprazygomatic maxillary nerve (SZMN) blocks to reduce pain and opioid use after pediatric intracapsular adenotonsillectomy and to measure recovery duration and incidence of complications. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, blinded, prospective single-center tertiary pediatric hospital that included 60 pediatric patients (2-14 years old) scheduled for intracapsular adenotonsillectomy from November 2021 to March 2023. Patients were excluded for having combined surgical procedures, developmental delay, coagulopathy, chronic pain history, known or predicted difficult airway, or unrepaired congenital heart disease. Participants were randomized to receive bilateral SZMN blocks (block group) or not (control group). INTERVENTION: SZMN block administered bilaterally under general anesthesia for intracapsular adenotonsillectomy. PRIMARY OUTCOMES AND MEASURES: Opioid consumption, FLACC (Face, Legs, Activity, Cry, Consolability) scores, and rates of opioid-free postanesthesia care unit (PACU) stay. Secondary outcomes were recovery duration and incidence of adverse effects, ie, nausea, vomiting, block site bleeding, and emergency delirium. RESULTS: The study population included 53 pediatric patients (mean [SD] age, 6.5 [3.6] years; 29 [55%] females; 24 [45%] males); 26 were randomly assigned to the SZMN block group and 27 to the control group. The mean (SD) opioid morphine equivalent consumption during PACU stay was 0.15 (0.14) mg/kg for the 27 patients in the control group compared with 0.07 (0.11) mg/kg for the 26 patients in the block group (mean difference, 0.08; 95% CI, 0.01-0.15; Cohen d, 0.64). The block group had a higher incidence of opioid-free PACU stays (n = 7 patients; 58%) compared with the control group (n = 15 patients; 26%) (mean difference, 32%; 95% CI, 5%-53%). Patients in the block group experienced lower FLACC scores (0.7 vs 1.6; mean difference, 0.9; 95% CI, 0.2-1.6; Cohen d, 0.7). The overall occurrence of adverse events was similar in the 2 groups, with no reported nerve block-related complications. CONCLUSIONS AND RELEVANCE: The results of the randomized clinical trial indicate that SZMN blocks are a useful adjunct tool for managing postoperative pain in pediatric intracapsular adenotonsillectomy. Use of these blocks during adenotonsillectomy provided clinically meaningful reductions of postoperative opioid consumption with a low risk of complications. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04797559.
引用
- Lin C, Abboud S, Zoghbi V, et al. Suprazygomatic Maxillary Nerve Blocks and Opioid Requirements in Pediatric Adenotonsillectomy: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38780948. doi:10.1001/jamaoto.2024.1011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。